Feasibility of combining high-dose-rate prostate brachytherapy with dose intensification to the MRI dominant lesion followed by real-time adaptive MR-guided pelvic radiotherapy for high-risk prostate cancer
Brachytherapy · 2026
DOI: 10.1016/j.brachy.2025.10.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brachytherapy, 2026. Verfasst von Gil'ad N Cohen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, NYU Grossman School of Medicine, New York, NY. Electronic address: gil'ad.cohen@nyulangone.org. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Brachytherapy, Radiotherapy, Image-Guided, Radiosurgery. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Optimizing radiotherapy delivery for higher-risk prostate cancer often requires dose escalation while minimizing dose to surrounding normal tissues. We report on the feasibility of combining high-dose-rate (HDR) brachytherapy with dose intensification to the dominant intra-prostatic lesion (DIL) followed by magnetic resonance-guided stereotactic body radiotherapy (MRgSBRT). METHODS AND MATERIALS: Eighty-eight patients were treated with a single fraction of 15-Gy HDR brachytherapy boost followed by MRgSBRT to prostate, or prostate and pelvic lymph nodes, to a dose of 25 Gy in five fractions. The DIL noted on multi-parametric MR imaging was defined as a PIRADS-4/-5 lesion with an associated diffusion-weighted abnormality(s), and was intraoperatively boosted during brachytherapy to 120% of the prescription dose. Dosimetric objectives included D99% >120% to the DIL, D1%
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, NYU Grossman School of Medicine, New York, NY. Electronic address: gil'ad.cohen@nyulangone.org.
- Department of Radiation Oncology, NYU Grossman School of Medicine, New York, NY.
Zitieren
APA
Cohen, G. N., Gurewitz, J., Johnson, J., Cooney, J., Shi, Y., Adler, H., Long, M., Byun, D. J., & Zelefsky, M. J. (2026). Feasibility of combining high-dose-rate prostate brachytherapy with dose intensification to the MRI dominant lesion followed by real-time adaptive MR-guided pelvic radiotherapy for high-risk prostate cancer. Brachytherapy. https://doi.org/10.1016/j.brachy.2025.10.013
Vancouver
Cohen GN, Gurewitz J, Johnson J, Cooney J, Shi Y, Adler H, et al. Feasibility of combining high-dose-rate prostate brachytherapy with dose intensification to the MRI dominant lesion followed by real-time adaptive MR-guided pelvic radiotherapy for high-risk prostate cancer. Brachytherapy. 2026. doi:10.1016/j.brachy.2025.10.013
BibTeX
@article{Cohen2026,
author = {Cohen, Gil'ad N and Gurewitz, Jason and Johnson, Jennifer and Cooney, Jeffrey and Shi, Yuhao and Adler, Harry and Long, Matthew and Byun, David J and Zelefsky, Michael J},
title = {Feasibility of combining high-dose-rate prostate brachytherapy with dose intensification to the MRI dominant lesion followed by real-time adaptive MR-guided pelvic radiotherapy for high-risk prostate cancer},
journal = {Brachytherapy},
year = {2026},
doi = {10.1016/j.brachy.2025.10.013}
}
EUVIMED